Streetbeat News

Regulatory

SCLX

Scilex Holding Company (SCLX) has responded to Health Canada's questions regarding the product composition of ELYXYB, an FDA-approved oral solution for acute migraine treatment. ELYXYB is under review by Health Canada for approval, with a decision expected in approximately 12 months. The drug is noted for its fast action and potential for low gastrointestinal side effects compared to other NSAIDs. The Canadian migraine therapeutics market is estimated to reach $400 million by 2025.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 1:04 pm

EH

NVEI

TSVT

Nuvei's shares surged 33% amid reports of buyout talks with Advent International. 2seventy Bio's stock jumped 50% following an FDA Advisory Committee's favorable vote on Abecma for multiple myeloma. EHang's shares increased 17% as the company started selling its EH216-S flying taxi on Taobao.

Portfolio Pulse from ryanfaloona@benzinga.com

March 18, 2024 | 12:44 pm

CTXR

Citius Pharmaceuticals announced that the FDA has accepted the BLA resubmission for LYMPHIR, a treatment for adults with relapsed or refractory cutaneous T-cell lymphoma. The FDA has set a PDUFA target action date of August 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:37 pm

NRXP

NRx Pharmaceuticals plans to distribute 49% of HOPE Therapeutics stock and a 1% royalty right on Ketamine sales to its shareholders. The Board of Directors has authorized necessary steps to effectuate this dividend and royalty rights distribution, pending completion of legal, accounting, and regulatory requirements.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:35 pm

ATOS

Atossa Therapeutics has regained compliance with Nasdaq's minimum bid price listing requirements, ensuring its continued listing on the exchange. This development is crucial for maintaining investor confidence and access to capital markets.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:31 pm

DERM

Journey Medical Corporation has announced that the FDA has accepted its New Drug Application for DFD-29, a medication intended for the treatment of rosacea. This marks a significant milestone for the company as it moves closer to potentially bringing a new treatment option to the market for those suffering from rosacea.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:31 pm

CEG

Constellation (NASDAQ:CEG) has issued the first corporate green bond in the U.S. for $900 million with a 30-year term to finance nuclear energy projects. This initiative underscores the role of nuclear energy in achieving sustainability goals and marks a significant step in green financing. The bond will fund investments in maintenance, expansion, and life extensions of nuclear power generation. Crédit Agricole CIB served as the Green Structuring agent for this offering, which aligns with the Green Bond Principles and Green Loan Principles.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 12:22 pm

RTC

Baijiayun Group Ltd (NASDAQ:RTC), an AI video solution provider, received a Nasdaq notice for not meeting the minimum bid price requirement. The company's share price has been below $1.00 for 30 consecutive trading days, violating Rule 5450(a)(1).

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 12:18 pm

BWA

LEV

The California Energy Commission awarded BorgWarner Inc. and partners Fermata Energy and The Lion Electric Company a $3M grant for a Vehicle-to-Grid project to support California school districts with electric school buses. This initiative aims to enhance energy management and transition to electric buses, providing grid-supporting and cost-saving solutions.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:50 am

GOOGL

NVDA

QQQ

SPY

Stock futures indicate a strong open, driven by Nvidia's AI conference and potential Alphabet-Apple partnership, despite concerns over Fed's upcoming meeting and recent inflation data. Nvidia and Alphabet stocks rose in premarket trading, while the broader market showed mixed reactions to inflation and interest rate expectations. Upcoming economic data and Fed decisions are anticipated to further influence market direction.

Portfolio Pulse from Shanthi Rexaline

March 18, 2024 | 11:37 am